5 May 2020 - Treatment of stage IIB–IV melanoma due to genetic mutations that disproportionately affect paediatric patients.

Mateon Therapeutics announced today that the US FDA granted rare paediatric disease designation for CA4P/fosbretabulin for the treatment of of stage IIB–IV melanoma due to genetic mutations that disproportionately affect paediatric patients as a drug for a “rare paediatric disease”.

Read Mateon Therapeutics press release